Quick Answer
REGENEREX PHARMA, INC. reported Total Revenue of $1.8 thousand for fiscal year 2021.
REGENEREX PHARMA, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $1.8K -31.9% |
$2.6K |
| Net Income | -$2.53M +28.7% |
-$3.54M -2480.5% |
-$137.3K +29.8% |
-$195.6K +44.7% |
-$353.8K -417.0% |
$111.6K +219.2% |
| Total Assets | $1.26M +64.8% |
$766.7K +11624.7% |
$6.5K -57.3% |
$15.3K +46.3% |
$10.5K -96.0% |
$259.2K +145.4% |
| Cash and Equivalents | $653.0K +175444.4% |
$372.00 -67.2% |
$1.1K -57.0% |
$2.6K -61.8% |
$6.9K +26.4% |
$5.5K -93.8% |
| Long-Term Debt | — | $184.2K | — | — | — | — |
| Stockholders Equity | -$4.16M -2.3% |
-$4.06M -261.7% |
-$1.12M -13.9% |
-$985.6K -18.0% |
-$835.0K -73.5% |
-$481.3K -30.2% |
| R&D Expense | $662.5K -72.4% |
$2.40M | — | — | — | — |
| Operating Income | -$1.83M +47.3% |
-$3.47M -3503.8% |
-$96.2K +23.8% |
-$126.3K -190.9% |
-$43.4K +43.6% |
-$77.0K +16.1% |
| Gross Profit | — | — | — | — | -$244.9K -27434.5% |
$896.00 |
| Shares Outstanding | 281.07M +1.0% |
278.23M +0.4% |
277.11M +0.0% |
277.11M +118.0% |
127.11M +0.0% |
127.11M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2020 | $181.00 | -89.2% | +50.8% |
| Net Income | September 30, 2025 | -$814.0K | -53.7% | -22.7% |
| Total Assets | September 30, 2025 | $617.8K | -2.4% | -19.1% |
| Cash and Equivalents | September 30, 2025 | $11.7K | +3865.6% | -93.2% |
| Long-Term Debt | March 31, 2024 | $184.2K | — | — |
| Stockholders Equity | September 30, 2025 | -$4.70M | +1.2% | -3.3% |
| R&D Expense | September 30, 2025 | $136.4K | — | +685.0% |
| Operating Income | September 30, 2025 | -$786.7K | -204.5% | -24.1% |
| Gross Profit | December 31, 2020 | -$183.00 | -112.4% | -312.8% |
| Shares Outstanding | September 30, 2025 | 281.75M | +1.2% | +0.2% |
- REGENEREX PHARMA, INC. reported Total Revenue of $1.8 thousand for fiscal year 2021.
- REGENEREX PHARMA, INC. showed a decrease of -31.9% in Total Revenue compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported Net Income of -$2.53 million for fiscal year 2025.
- REGENEREX PHARMA, INC. showed an increase of +28.7% in Net Income compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported Total Assets of $1.26 million for fiscal year 2025.
- REGENEREX PHARMA, INC. showed an increase of +64.8% in Total Assets compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported Cash and Equivalents of $653.0 thousand for fiscal year 2025.
- REGENEREX PHARMA, INC. showed an increase of +175444.4% in Cash and Equivalents compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported Long-Term Debt of $184.2 thousand for fiscal year 2024.
- REGENEREX PHARMA, INC. reported Stockholders Equity of -$4.16 million for fiscal year 2025.
- REGENEREX PHARMA, INC. showed a decrease of -2.3% in Stockholders Equity compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported R&D Expense of $662.5 thousand for fiscal year 2025.
- REGENEREX PHARMA, INC. showed a decrease of -72.4% in R&D Expense compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported Operating Income of -$1.83 million for fiscal year 2025.
- REGENEREX PHARMA, INC. showed an increase of +47.3% in Operating Income compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported Gross Profit of -$244.9 thousand for fiscal year 2021.
- REGENEREX PHARMA, INC. showed a decrease of -27434.5% in Gross Profit compared to the prior fiscal year.
- REGENEREX PHARMA, INC. reported Shares Outstanding of 281.07 million shares for fiscal year 2025.
- REGENEREX PHARMA, INC. showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: